Some derivatives of the 4-arylsalicylketoximes series displayed inhibitory effects on glucose transport and on cell proliferation in several biological assays,[1] resulting to be effective GLUT1 inhibitors also in GLUT1-containing giant vesicles. GLUT1 is one of the 14 glucose transporter isoforms, widely overexpressed in many cancer types. Thus, for the discovered properties, the oximes of interest represent interesting candidates for anticancer therapy. Variously substituted 4-arylsalicylketoximes (3, Fig.1) were synthetized via Suzuki cross-coupling and a subsequent condensation of the resulting biaryl-ketone intermediates with hydroxylamine hydrochloride. [1] Rat GLUT1 membrane proteins were produced by Pichia Pastoris cultures, and purified following GLUT1 purification protocols, [2] which were largely revised to avoid the protein cleavage. Compounds 3a, 3b, 3e, and 3f efficiently inhibited glucose uptake in GLUT1-containing giant vesicle assays. [3] To study the nature of the binding process between GLUT1 and the synthetic compounds, many crystallization attempts were set up with 3a and 3e using Lipidic Cubic Phase method, which produced many small crystals. Since many isoforms of GLUTs are overexpressed in cancer cells, inhibition of other GLUT isoforms, such as GLUT3, will be tested in the near future. In conclusion, 4-arylsalicylketoximes showed good inhibition of GLUT1 isoform. First results from GLUT3-giant vesicles assays revealed that, within this series of compounds, 3a is the most selective GLUT1-inhibitor. Further assays with GLUTs-containing giant vesicle and crystallization attempts are currently underway. [1] Granchi C, Qian Y, Lee H.Y, Paterni I, Pasero C, Iegre J, Carlson K. E, Tuccinardi T, Chen X, Katzenellenbogen J. A, Hergenrother P. J, Minutolo F, ChemMedChem. 2015; 1892–1900. [2] Venskutonyté R, Elbing K, Lindkvist-Petersson K, Methods Mol Biol. 2018; 1713, 1–13. [3] Hansen J.H, Elbing K, Thompson J.R, Malmstadt N, Lindkvist-Petersson K, Chem. Commun. 2015; 51, 2316–2319.
Salicylketoximes as inhibitors of Glucose Transporters
Serena Fortunato
Primo
;Carlotta Granchi;Filippo MinutoloUltimo
2018-01-01
Abstract
Some derivatives of the 4-arylsalicylketoximes series displayed inhibitory effects on glucose transport and on cell proliferation in several biological assays,[1] resulting to be effective GLUT1 inhibitors also in GLUT1-containing giant vesicles. GLUT1 is one of the 14 glucose transporter isoforms, widely overexpressed in many cancer types. Thus, for the discovered properties, the oximes of interest represent interesting candidates for anticancer therapy. Variously substituted 4-arylsalicylketoximes (3, Fig.1) were synthetized via Suzuki cross-coupling and a subsequent condensation of the resulting biaryl-ketone intermediates with hydroxylamine hydrochloride. [1] Rat GLUT1 membrane proteins were produced by Pichia Pastoris cultures, and purified following GLUT1 purification protocols, [2] which were largely revised to avoid the protein cleavage. Compounds 3a, 3b, 3e, and 3f efficiently inhibited glucose uptake in GLUT1-containing giant vesicle assays. [3] To study the nature of the binding process between GLUT1 and the synthetic compounds, many crystallization attempts were set up with 3a and 3e using Lipidic Cubic Phase method, which produced many small crystals. Since many isoforms of GLUTs are overexpressed in cancer cells, inhibition of other GLUT isoforms, such as GLUT3, will be tested in the near future. In conclusion, 4-arylsalicylketoximes showed good inhibition of GLUT1 isoform. First results from GLUT3-giant vesicles assays revealed that, within this series of compounds, 3a is the most selective GLUT1-inhibitor. Further assays with GLUTs-containing giant vesicle and crystallization attempts are currently underway. [1] Granchi C, Qian Y, Lee H.Y, Paterni I, Pasero C, Iegre J, Carlson K. E, Tuccinardi T, Chen X, Katzenellenbogen J. A, Hergenrother P. J, Minutolo F, ChemMedChem. 2015; 1892–1900. [2] Venskutonyté R, Elbing K, Lindkvist-Petersson K, Methods Mol Biol. 2018; 1713, 1–13. [3] Hansen J.H, Elbing K, Thompson J.R, Malmstadt N, Lindkvist-Petersson K, Chem. Commun. 2015; 51, 2316–2319.File | Dimensione | Formato | |
---|---|---|---|
ABS_Fortunato_EWDSy_2018.pdf
accesso aperto
Descrizione: abstract
Tipologia:
Abstract
Licenza:
Creative commons
Dimensione
569.74 kB
Formato
Adobe PDF
|
569.74 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.